You searched for "outpatient"
Consent Part 2
See Part 1 on this topic here Case 1 A 77 year old lady presents to the Emergency Department confused and generally unwell. She is septic and, on imaging, is found to have a 9mm obstructing right sided proximal ureteric...ABC (Action Bladder Cancer) UK Setting up a support group for your patients - A guide for urology and cancer nurses working with bladder cancer patients
ABC UK are running an online Zoom session on Monday 18th August at 6:30pm, which is being run in response to requests from urology and cancer nurses, on how to set up and run a successful patient support group. There...Neuroendocrine bladder tumour
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...
Tissue-based biomarkers steering clinical decisions in patients with urothelial cancer
Biomarkers play an essential role in the diagnosis and treatment of urothelial cancer (UC), with PD-L1, FGFR, and MMR proteins being the most clinically established. These biomarkers, derived from histological specimens, guide therapeutic decisions for bladder cancer (BCa) and upper...Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...EAU (European Association of Urology) Talent Incubator Programme: Policy & Innovation
The randomised controlled trial (RCT) will remain one of the most important methods for medical advancements. A solid framework, an extensive network and financial resources are key factors in the success of a trial. In this module of the Talent Incubator Programme, we will address the practical side of conducting research and trials with support from policy experts, industry representatives and patient advocatesEAU (European Association of Urology) Masterclass on Focal therapy for localised prostate cancer
Focal Therapy (FT) is a promising treatment option aimed at improving the management of localised prostate cancer. This masterclass will provide you with an extensive review of the rationale for FT, the patient selection modalities and the available energy sources (HIFU, Cryo, IRE, Laser, Brachytherapy). Gain further knowledge and better understand the FT benefits.RSM (Royal Society of Medicine) Complexity and Complications: Navigating Advanced Prostate Cancer
This year’s RSM Cancer Day will focus on the evolving management of prostate cancer. With emerging evidence supporting radical prostatectomy in oligometastatic disease, the programme will examine patient selection, treatment strategies, and the latest advances for managing advanced-stage cases.
Patient-reported outcomes after prostate cancer treatment
This study used the survivorship (LIVESTRONG) care plan tool to identify patient-reported toxicities that occurred following treatment for prostate cancer. All patients had undergone treatments, which were considered to have similar oncological endpoints. The tool asked patients questions with regard...
